




PC/GB04/3117



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed 

Dated 5 August 2004

33.6.04 11.11.04


The
Patent
Office

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



1. Your reference

RSJ07868GB

2. Patent application number

(The Patent Office will fill in this part)

0316912.5

18 JUL 2003

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

OXFORD INSTRUMENTS SUPERCONDUCTIVITY
LIMITED

Old Station Way
Eynsham, Witney
Oxfordshire OX8 1TL

Patents ADP number (*if you know it*)

8189367001

If the applicant is a corporate body, give the country/state of its incorporation

GB

4. Title of the invention

THERAPEUTIC TREATMENT

5. Name of your agent (*if you have one*)

Gill Jennings & Every

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

Broadgate House
7 Eldon Street
London
EC2M 7LH

Patents ADP number (*if you know it*)

745002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number
(*if you know it*)

Date of filing
(*day / month / year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(*day / month / year*)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if:*

YES

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	1
Description	21
Claim(s)	4
Abstract	1
Drawing(s)	10 + 10

10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	-
Request for substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	NO

11. For the applicant
Gill Jennings & Every

I/We request the grant of a patent on the basis of this application.

Signature

John Jappy

Date

18 July 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

JAPPY, John William Graham

020 7377 1377

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

Continuation Sheet

Our reference: RSJ07868GB

Applicant Details

CELLTECH R & D LIMITED
208 Bath Road
Slough
Berkshire SL1 3WE
United Kingdom

8721 485001

THERAPEUTIC TREATMENT

Field of the Invention

This invention relates to the treatment of disorders associated with the accumulation of a biological material or an aberrant cellular or tissue structure. More particularly, this invention relates to the treatment of such disorders by mechanical disruption.

Background to the Invention

In recent years, there have been many advances in the treatment of disorders associated with aberrant cellular or tissue structures, by the selective targeting of the structures with appropriate therapeutic agents. In particular, in the context of tumour therapy, there have been significant advances in technologies that permit the localisation of appropriate chemotherapies at the tumour site. However, chemotherapy is often compromised by adverse systemic toxicity, which limits the dose of drug that can be administered, or is limited by the appearance of multi-drug resistance. One particular difficulty results from the need to control the cytotoxicity until after localisation at the tumour site, to prevent non-specific cell damage (Eaton, Immunoconjugates: Current Status and Future Potential, *Journal of Drug Targeting*, 2002; 10(7):525-527).

More recently, there have been investigations into the use of magnetic particles to treat tumours via a process referred to as "hyperthermia". This process relies on localising magnetic particles at a tumour site and applying a magnetic field from a high frequency AC magnet, to induce magnetic hysteresis loss. The heat dissipating from the particles damages the tumour cells resulting in cell death. A description of this process is found in Jones *et al.*, *Int. J. Hyperthermia*, 2002; 18(2): 117-128.

The benefit of this proposed therapy is that the magnetic particles can be administered to a patient in a relatively inert form, and the destructive ability of the particles can be induced selectively, when the particles are localised at the target site. This avoids the uncontrolled cytotoxicity that may be experienced using chemotherapeutic agents.

US 6514481 describes the targeting of spherical magnetic nanoparticles less than 100 nm in diameter, to a cellular location, with subsequent application of a DC magnetic field, to destroy the targeted cells. The nanoparticles are prepared from iron oxide, e.g. Fe_2O_3 , and an applied magnetic field of 7 Tesla is shown to be required to achieve *in vitro* cell death.

While the results achieved using this process are of interest, the requirement for a very strong magnetic field limits the suitability of the process for clinical applications due to the high cost of whole-body hardware for generating fields above about 2 Tesla, and the danger of damaging healthy tissue due to causing motion in non-localised naturally occurring or contaminant particles.

There is therefore a need for improved processes for inducing cell death using magnetic particles.

Summary of the Invention

The present invention is based, at least in part, on the understanding that effective destruction of materials, including biological/cellular structures can be achieved using selected magnetic particles at a relatively low magnetic field strength.

According to a first aspect of the invention, a method for disrupting a material, comprises the steps of:

- (i) localising one or more magnetic particles at or within the material;
and
- (ii) applying a magnetic field to the or each magnetic particle, to induce particle movement and thereby disrupt the material, wherein the or each magnetic particle has intrinsic magnetization, said magnetization being stabilised by inherent magneto-crystalline anisotropy and/or by shape anisotropy.

According to a second aspect of the invention, magnetic particles, as defined above, are used in the manufacture of a medicament for administration to a patient to treat a disorder associated with a cellular or tissue structure, or the accumulation of an undesirable biological material, wherein the or each

particle is preferably adapted to localise at or within the structure or material, and wherein the treatment is intended to be carried out by applying a magnetic field, to induce the or each particle to move, to thereby disrupt the structure or material, wherein the or each magnetic particle has intrinsic magnetization, said magnetization being stabilised by inherent magneto-crystalline anisotropy and/or by shape anisotropy.

Contrary to the processes of the prior art that rely on hyperthermia to achieve cell death, the present invention relies on inducing movement of the particles with sufficient torque to achieve a mechanical disruption of the cell structure or other biological material. With the correct particle design, particle movement can be achieved using a magnetic field strength significantly lower than that disclosed in US 6514481, thereby permitting clinical development of the therapy.

According to a third aspect of the present invention, apparatus for disrupting a material, including a cellular or tissue structure, comprises a magnetic field generator for generating a magnetic field in a working volume; one or more magnetic particles localised at or in the material in the working volume, the or each magnetic particle having intrinsic magnetization, said magnetization being stabilised by inherent magneto-crystalline anisotropy and/or by shape anisotropy; and a control system for causing a change in the magnetic field in the working volume with respect to the material.

According to a fourth aspect of the invention, a magnetic particle having intrinsic magnetization, said magnetization being stabilised by inherent magneto-crystalline anisotropy and/or by shape anisotropy, comprises a targeting moiety bound thereto.

Description of the Drawings

The invention is described with reference to the accompanying drawings, wherein:

Figures 1a to 1c illustrate the differences in magnetisation M of "hard" and "soft" magnetic nano-particles, relative to an applied magnetic field H ;

Figure 2 illustrates the dependence of coercivity on particle size;

Figures 3a and 3b illustrate the oblate and prolate spheroid configurations preferred for "soft" magnetic particles; and,

Figures 4-7 are schematic diagrams of different types of magnetic field generating apparatus.

Description of the Invention

The particles for use in the present invention may be of any suitable size, but will preferably be on the nano scale, i.e. less than 1 μm . The particles may therefore be referred to as nanoparticles. Preferably the particles comprise a magnetic core within a bio-compatible coating, the particle core being from 50 nm to 500 nm in size, more preferably approximately 100 to 150 nm in size. The optimum size will depend, at least in part, on the choice of material. Further reference to the size of the particles should be taken as referring to the magnetic core material and not the total size with any coating, unless there is a statement to the contrary.

In order to be efficacious, a sufficiently large force must be generated to damage critical elements of the cell's structure. To a large extent this depends on the mechanical properties of the cell (in turn described by complex properties of cytoskeletal viscoelasticity, rheology, tensegrity, etc). However, current research suggests that a force of around 100pN is sufficient to break microtubules (a key cellular structure associated with intracellular transport). For the purposes of describing the invention the embodiments given in this application therefore assume a damage threshold force of 100pN and describe apparatus capable of generating this threshold force. It will be apparent that the invention is in no way intended to be limited to a threshold force of either above or below 100pN.

To generate the damage threshold force efficiently requires careful consideration of the practical limitations on both the design of the magnetic core of the nanoparticle, and the whole body therapy magnet. The design parameters for the magnetic core are:

- size
- shape

— material

and for the magnet the primary design parameters are:

- size of treatment region (ie: whole body or localised)
- magnetic field strength in the treatment region
- time dependence of magnetic field strength within the treatment region

The preferred time dependence of the applied magnetic field depends strongly on the viscoelastic properties of the cell. The optimum time dependence must be evaluated by experimentation, but must also fall within practical constraints of magnet hardware, which will be discussed in due course.

For the nanoparticle to be internalised within the cell, it must be of an appropriate size. The preferred maximum dimension of the particle including bio-compatible coating is therefore about 200nm.

Particles having a magnetic moment \underline{m} will experience torque and translation forces in an applied magnetic field of flux density \underline{B} . The torque acts to align the magnetic moment with the applied field direction and is given by

$$\underline{\Gamma} = \underline{m} \times \underline{B}$$

The translation force, which acts to move the magnetic moment along the applied field gradient towards the region of highest flux density, is given by

$$\underline{F} = -\text{grad}(\underline{m} \cdot \underline{B})$$

The variation of \underline{B} across the nanoparticle is negligible, so this becomes:

$$\underline{F} = -\underline{m} \cdot \text{grad}(\underline{B})$$

The magnetic field must have a very large gradient to generate a substantial translation force. In fact the translation force turns out to be negligible in all practical arrangements and henceforth only torque will be considered.

The peak force couple (F_c) on a particle experiencing torque $\underline{\Gamma}$ and having dimension d (measured in a direction orthogonal to $\underline{\Gamma}$) occurs when \underline{m} is orthogonal to \underline{B} :

$$F_c = |\underline{\Gamma}|_{\text{peak}} / d = |\underline{m}||\underline{B}| / d$$

It is clear that to maximise the torque or force couple we need to maximise \underline{B} and \underline{m} . We also want to minimise \underline{B} to keep down the therapy magnet cost, so we are left with the optimisation problem: "maximise $|\underline{m}|$ to meet the damage force threshold with minimum $|\underline{B}|$ ".

The magnetic moment \underline{m} is related to the particle's magnetization \underline{M} by volume integration:

$$\underline{m} = \int_V \underline{M} dV$$

Writing M_{eff} as the effective or net magnetization averaged over the whole particle including self-demagnetizing effects:

$$|\underline{m}| = V \cdot M_{\text{eff}}$$

so that the peak force couple is given by

$$F_c = VM_{\text{eff}}B / d$$

from which we can conclude that the magnetic flux density B , the particle's volume V and effective magnetization M_{eff} must be as large as possible.

The magnetic flux density needed to generate the required force couple is therefore:

$$B = F_c d / VM_{\text{eff}} \quad (1)$$

Calculations using equation (1) and data from Table 1 (below) show that the minimum preferred size for the magnetic core using the preferred material

(hexaferrite) is about 50nm. Particles smaller than this require much stronger magnetic fields to induce cell lysis. Rare-earth materials allow the use of smaller particles at practical field strengths ($<1\text{T}$), but if rare-earth materials are to be used, they require a coating of an inert biocompatible material to avoid toxicity problems.

Figure 1a shows the major magnetization loop of a bulk sample of typical ferromagnetic material, plotting magnetization M against applied field H . A ferro- or ferri- magnetic material is composed of $\sim 10^{12}$ to 10^{15} domains per cubic centimetre, each domain being a fully magnetized single crystal. The remanent magnetization in zero applied field (M_R) depends the relative orientation of the domains, which in turn depends on the material properties and domain wall structure. The applied field required to reduce the sample's magnetization to zero is called the coercive field H_C , or the coercivity. At sufficiently high applied field all domains become aligned, and the magnetization cannot increase beyond the saturation value (M_{sat}).

The properties of magnetic materials at nano-scale can be substantially different to their bulk properties. This is because nano-scale particles typically comprise only a few, or a single, magnetic domain.

In the presence of an external magnetic field the nanoparticle's magnetization will try to align with the field, as previously described. Whether this is achieved by physical rotation of the particle, or re-alignment the magnetization direction within the particle's crystal lattice is determined by the particle's coercivity (H_C), the former behaviour being more likely for high coercivity particles. For the purposes of the invention, physical rotation of the particle is clearly desirable, whilst rotation of magnetization direction within the particle's crystal lattice is undesirable. It is therefore necessary to understand how the coercivity of a nanoparticle can be maximised. Figure 1b illustrates the difference between the M - H loops of high and low coercivity nanoparticles. A particle with high coercivity is magnetically "hard" whereas one with low coercivity is "soft".

The coercivity depends on particle size, as shown in Figure 2. Below a critical diameter d_0 , the nanoparticle is a single domain (SD), above d_0 it is

composed of many domains (MD). The transition region where the particle has a few domains is called the pseudo-single domain range (PSD). The coercivity of the particle peaks near d_0 , falling as the particle size and number of domains increases, and also as the size of a single domain decreases. Below a second critical diameter d_s the coercivity is effectively nil and the particle displays superparamagnetic behaviour.

Furthermore, a single domain nanoparticle has remanent magnetization equal to the saturation magnetization of a bulk sample, (ie: $M_R \approx M_{sat}$), as shown in Figure 1b. Multi-domain particles have lower remanent magnetization (Figure 1a).

The variation of coercivity with particle size can be related to material properties as follows. The lower critical size, d_s , is controlled by the Neel relaxation time, τ_N . For a single domain this is:

$$\tau_N = \frac{1}{f_0 \cdot e^{\frac{-K_U \cdot V}{k_B \cdot T}}}$$

where k_B is Boltzmann's constant, T is absolute temperature, V is particle volume, K_U is the magneto-crystalline anisotropy (an intrinsic property of the material) and f_0 is the Neel frequency (10^9 Hz). The Neel time constant determines how quickly the magnetization can rotate within the crystal lattice in response to a change of applied field; it is determined by the competing effects of thermal energy ($k_B T$) and magneto-crystalline energy ($K_U V$). As $V \propto d^3$ it will be appreciated from the equation above that τ_N is extremely sensitive to particle size. At constant temperature there exists a critical particle diameter d_s for which $\tau_N \sim 1s$:

$$d_s = 3.4 \cdot \left(\frac{k_B \cdot T}{K_U} \right)^{\frac{1}{3}} \quad (2)$$

For particles smaller than d_s , thermal energy dominates, τ_N is very short and the nanoparticle's magnetization can rotate freely within the crystal lattice. For single domain particles with diameter greater than d_s the relaxation time is very long and the magnetization is effectively locked to the lattice.

The upper critical size d_0 occurs when the energy cost of creating a domain wall is balanced by a net overall reduction in stored magneto-static energy. The magneto-static energy per unit volume is given by:

$$e_{\text{mag}} = \frac{\mu_0}{2} \cdot D \cdot M_{\text{sat}}^2$$

where D is a shape demagnetizing factor. The domain wall energy per unit area is given by:

$$e_{\text{wall}} = 4 \cdot \sqrt{A \cdot K_U}$$

where A is the exchange stiffness, of the order 10^{-12} J/m for ferromagnetic materials.

Hence d_0 may be determined by equating the energy of a single domain particle with that of a two domain particle having the same volume. Assuming the particle is a sphere (and thus $D \sim 1/3$):

single domain energy equals the two domain

$$e_{\text{mag}} \cdot \left[\frac{4}{3} \cdot \pi \cdot \left(\frac{d_0}{2} \right)^3 \right] = e_{\text{mag}} \cdot \frac{\left[\frac{4}{3} \cdot \pi \cdot \left(\frac{d_0}{2} \right)^3 \right]}{2} + e_{\text{wall}} \cdot \left[\pi \cdot \left(\frac{d_0}{2} \right)^2 \right]$$

which when simplified results in an expression for d_0 :

$$d_0 = 72 \cdot \frac{\sqrt{A \cdot K_U}}{\mu_0 \cdot M_{\text{sat}}^2} \quad (3)$$

For sizes above d_0 the particle may re-align its net magnetization in response to a change in applied magnetic field by domain wall movement. Hence coercivity falls as the number of domains increases.

Particles with diameter in the range $d_s < d < d_0$ are referred to as "blocked" or "locked" single domain particles.

The peak coercivity occurs near d_0 and is given approximately by:

$$H_{C_peak} = \frac{2 \cdot K_U}{\mu_0 \cdot M_{sat}} \quad (4)$$

For the purposes of the invention it is desirable that the particle is either in the locked single domain range or in the lower part of the multi-domain range ($d < \sim 2d_0$), when coercivity is maximised.

Table 1 lists the material properties K_U and M_{sat} of various magnetic materials. Figure 1c shows M-H loops approximately to scale for nanoparticles made from these materials.

	K_U (kJ/m ³)	M_{sat} (kA/m)
Magnetite	15	470
Hexaferrite	100	240
SmCo	10000	800

Table 1: Material properties of some magnetic materials

Table 2 shows the parameters d_s , d_0 , and H_{C_peak} for the same materials, as calculated from equations (2), (3) and (4).

	d_s (nm)	d_0 (nm)	H_{C_peak} (kA/m)
Magnetite	22	32	51
Hexaferrite	11.7	315	664
SmCo	2.5	283	19900

Table 2: Parameters d_s , d_0 , and H_{C_peak} for nanoparticles made from various magnetic materials

If the applied field is less than the particle's coercive field ($H_{applied} < H_c$), the magnetization will remain effectively locked to the crystal lattice, and the particle will experience a torque acting to physically re-orient it with the applied field direction. However, if the applied field is greater than the particle's coercive field ($H_{applied} > H_c$), the magnetization will rotate within the crystal lattice to align with the applied field direction.

A key aspect of the invention is therefore to provide particles in which the magnetization is locked to the crystal lattice, or "stabilised", for an applied magnetic field which is sufficiently strong to induce cell killing torque, but much lower than that used in prior art.

This is achieved by one of two alternative methods. The first method suits magnetically "hard" particles, made from materials having inherently high magnetocrystalline anisotropy ($K_u > 10^5$), for example rare-earth alloys (eg: Sm_2Co_{17}), or hexaferrites (eg: $BaFe_{12}O_{19}$), or tetragonal FePtCr or CoPtCr alloys ($K_u \sim 10^8$). The second method suits magnetically "soft" particles, made from materials having inherently low magneto-crystalline anisotropy ($K_u < 10^5$), such as ferrous and ferric oxide (Fe_2O_3 and Fe_3O_4 , ie: magnetite).

The two methods are illustrated here by way of numerical examples, assuming the cell killing threshold torque is 100pN and the particle is a 100nm diameter sphere (for which $M_{eff} \sim (2/3)M_{sat}$). Considering first hard particles, equation (1) gives the required flux density as 0.036T for SmCo and 0.12T for hexaferrite. Converting to field intensity (using $H = B/\mu_0$, where μ_0 is the permeability of free space) the required field is 28 kA/m for SmCo and 95 kA/m for hexaferrite. Table 2 shows that a 100nm diameter particle made from either material is inside the locked single domain size range. The coercivity H_c can be estimated by extrapolation assuming a parabolic fit in the locked SD range, giving about 11000 kA/m for SmCo and 330 kA/m for hexaferrite. So $H_{applied} < H_c$ in both cases and the magnetization is locked to the crystal lattice, as required.

The key requirement in the first method is to use materials with intrinsically high magneto-crystalline anisotropy ($K_u > 10^5 \text{ J/m}^3$).

Now turning to soft particles, applying equation (1) with $M_{\text{eff}} \sim (1/3)M_{\text{sat}}$ (allowing 33% reduction in magnetization due to self de-magnetization and a further, conservative, 33% drop for multi-domain effects) gives a required flux density for a 100nm magnetite sphere as 0.12T ($\sim 100 \text{ kA/m}$). Table 2 shows that a 100nm magnetite particle is well into the multi-domain range, so the particle's coercivity will be significantly lower than the peak of 51 kA/m, probably by a factor of 3 or more. Hence $H_{\text{applied}} > H_c$ and the magnetization will start to rotate within the lattice at an applied field much less than that required to induce cell killing torque. If the particle diameter is reduced to 32nm so that the coercivity is maximised at $\sim 51 \text{ kA/m}$, the required field rises to 950 kA/m (because the particle's volume is now much lower). This too is much greater than the peak coercivity. In fact the magnetization cannot be stabilised for any particle size and the threshold torque cannot be reached. At face value this problem appears to preclude the use of materials with low magneto-crystalline.

However, it has been found that the magnetization can be effectively locked to the crystal lattice if the magnetic nanoparticles are substantially non-spherical in shape. In other words, shape anisotropy is used as a substitute magneto-crystalline anisotropy. In a particularly preferred embodiment, the soft particles are in the approximate form of either an oblate spheroid with an aspect ratio of approximately 1:2.5 (see Figure 3a), or a prolate spheroid with an aspect ratio of approximately 1.6:1 (Figure 3b).

The peak force couple for non-spherical soft particles will occur when the angle between the particle's long axis and the applied field is 45° . The flux density required to generate a maximum force couple F_c on a soft spheroid nanoparticle having major axis d , is given by

$$B = \alpha F_c / M_{\text{eff}} d^2 \quad (5)$$

where the shape factor $\alpha = 24.4$ for the optimum oblate spheroid and 55.6 for the optimum prolate spheroid. Therefore the oblate spheroid (or "disk") generates over twice as much force as a prolate spheroid ("rod") with the same maximum dimension. However, the rod has one long axis and two short, whilst the disk has two long, and one short. The orientation of the nanoparticles within the target tissue will be random, so the rod-shaped particle is more likely to find itself at a significant angle to the applied magnetic field than the disk-shaped particle. They are both therefore considered equally preferred shapes.

We can calculate the range of magnetic flux density needed to apply a 100pN force couple to a 100nm nanoparticle using equation (1) for materials with high magneto-crystalline anisotropy and equation (5) for particles with low magneto-crystalline anisotropy. The results are contained in Table 3.

Particle with max dimension of 100nm	B for 100pN couple (T)
Magnetite (optimum disk shape)	0.52
Magnetite (optimum rod shape)	1.2
Hexaferrite (sphere)	0.12
SmCo (sphere)	0.036

Table 3: Flux density required to generate 100pN force couple in 100nm particles.

Therefore it is clear that magnetically hard particles require a much lower "activation" field strength (ie: field needed to generate threshold torque) compared to magnetically soft particles.

Biological tissue of living organisms can be expected to contain some naturally occurring magnetic material, such as cell magnetosomes (nano-scale magnetite particles occurring in some rare cell types), and iron or iron oxide particulate contamination accumulated over time from the environment. It is clearly desirable that the magnetic therapy does not induce cell damaging torque in these particles. As no control can be exercised over the composition, location

or size of the contaminant or natural particles, the only recourse is to minimise the applied field.

Being predominantly iron and iron-oxide the contaminant particles will behave as magnetically soft particles. If the targeted nanoparticles are magnetically hard they can be "activated" by a much weaker field than that required to activate the contaminant or naturally occurring particles. In addition to the advantage of lower cost magnet hardware, this is further reason for preferring to use magnetically hard particles or soft particles of the preferred shape.

The particles may be prepared with a coating of a bio-compatible material, which is biologically inert. Examples include polyethylene glycol, ethyleneglycol copolymers, dextrin, polymers and copolymers of hydroxyalkyl(meth)acrylamide, for instance, hydroxypropylmethacrylamide, and copolymers of styrene and maleic anhydride. Additional compounds include polyglutaric acid, carbohydrates and naturally occurring proteins such as albumin. The bonding can be either covalent or non-covalent. The coating will usually be applied to the particles prior to use in the method, however, it is envisaged that particles may attain a coating on administration, e.g. a coating of serum albumin. The preparation of coated particles is known in the art. For example, US 6048515, US 5460831 and US 5427767 all describe coated particles.

The particles may be localised at a target site using any convenient means, including the use of a targeting moiety. The targeting moiety may be any suitable molecule that permits selective targeting to the target site. Examples of suitable targeting moieties include antibodies and receptor ligands, e.g. hormones. Alternatively, localisation may be carried out using the magnetic properties of the particles, with a magnetic field directing the particles to the correct site of action.

In recent years, there has been a great deal of investigation into the use of polymers in the selective targeting of a tumour site. High molecular weight polymers achieve site-specific passive capture through the enhanced permeability and retention (EPR) effect. The EPR effect results from enhanced permeability of macromolecules or small particles within the tumour

neovasculature, due to the leakiness of its discontinuous endothelium. In addition to the tumour angiogenesis (hypervasculation) and irregular and incompleteness of vascular networks, the attendant lack of lymphatic drainage promotes accumulation of macromolecules that extravasate. This effect is observed in many solid tumours for macromolecular agents and lipids.

Suitable polymers with which have been used to target tumours by the EPR effect, include polyethylene glycol, ethyleneglycol copolymers, dextrin, polymers and copolymers of hydroxyalkyl(meth)acrylamide, for instance, hydroxypropylmethacrylamide, and copolymers of styrene and maleic anhydride. These may all be used in the present invention.

Improved targeting of the polymers may be achieved by attaching additional ligands to the polymers, e.g. attaching galactose ligands for selective targeting the liver. Antibodies may also be used in conjunction with the polymer to target the tumour site.

Antibodies are the preferred targeting moiety, and there are many examples known in the art of antibodies that have affinity for antigens expressed by aberrant biological structures, e.g. by tumour cells. For example, antibodies raised against the carcinoembryonic antigen (CEA) are known. A review of antibodies raised against human tumour antigens is found in Lloyd, *Basic and Clinical Tumour Immunology* (Herberman, Ed.), 1983: 159-214.

Any suitable antibody or fragment may be used in the present invention. Suitable antibodies include recombinant antibodies, antibodies from natural sources, e.g. human, molecules such as Fab fragments, Fab' fragments, F(ab')₂ fragments, Fv and SCFv. Antibodies that permit internalisation into a cell are a preferred embodiment of the invention. These so-called "internalising antibodies" are known to those skilled in the art. The antibodies will usually have an affinity for a target of at least 10⁻⁷M, preferably at least 10⁻⁹M and most preferably at least 10⁻¹¹M. The preparation of antibodies suitable for use in the invention will be apparent to those skilled in the art.

Examples of techniques used to prepare antibodies can be found in *Molecular Cloning: A Laboratory Manual*, 2nd Edition, Sambrook *et al.*, Cold

Spring Harbour, N. Y. (1989). Additional teachings can be found in US 4816397, US 4816567, GB 2188638 and GB 2209757.

In the preferred embodiment, the antibodies are bound to the magnetic particles. However, it is also envisaged that the antibody may be localised at the target site independently of the magnetic particles, with a suitable antigen being attached to the magnetic particles for targeting the antibody.

There may be more than one targeting moiety attached to each particle.

The targeting moiety may be bound to the magnetic particle through one or more linkages, which may be covalent or non-covalent. The targeting moiety may be attached to the magnetic particle using a cleavable linker molecule. Examples of suitable cleavable linkers are known in the art.

Attachment of the targeting moiety may be achieved using any suitable linker molecule that attaches directly to the magnetic particle or attaches to a coating on the magnetic particle. Suitable linker groups will be apparent to those skilled in the art and include: polyethylene glycol (PEG), polyols including polysaccharides and polycarboxylates. Attachment of antibodies to nanoparticles is disclosed in US 6514481.

In one embodiment, the magnetic particle (or its coating) is attached to the targeting moiety via a multidentate ligand which results in improved stability of the binding interaction. Multidentate ligands comprise linked multiple sites of attachment between the particle and the targeting moiety. ~~The targeting moiety~~ is therefore attached to the particle by more than one linkage, resulting in improved stability.

The magnetic particles may be used to target and disrupt any suitable material. Disruption may be carried out for a therapeutic or diagnostic purpose and targeting may be carried out *in vitro* or *in vivo*. Preferably, the material is a biological material, e.g. an aberrant cellular or tissue structure, more preferably a mammalian cellular or tissue structure. For example, the magnetic particles of the invention are particularly suitable for the treatment of a tumour which can be targeted due to the expression of specific tumour-associated antigens. The particles will localise at the surface of the cell membrane or may be internalised, prior to the application of the magnetic field. Once activated by the magnetic

field, the particles disrupt internal or external cellular structures, resulting in cell death. The particles are then removed from the body by normal excretory mechanisms such as macrophage action.

Tumours which may be treated using the present invention will be apparent to the skilled person. The tumours may be solid or liquid tumours (e.g. leukaemia), and may be macro or micro tumours.

The material may also be a cell comprising an infectious agent. The material may also be a multicellular or unicellular microorganism, e.g. a prokaryotic or eukaryotic microorganism. The material may also be viral or fungal.

In a separate embodiment, the particles may be used to disrupt or dislodge unwanted biological material at a target site. An example of this is in the treatment of atherosclerotic plaques. It is possible to localise the magnetic particles at this site of the plaque by denatured or oxidised LDL, and subsequent activation of the particles will reduce the density of the plaque by dislodging the sclerotic material. Antibodies that have affinity to plaques are discussed in US6379699.

The particles may be administered to a patient in a variety of ways. Preferably, the particles are formulated in compositions for parenteral administration, i.e. subcutaneous, intramuscular or intravenous administration. Accordingly, the invention provides compositions for parenteral administration which comprise the particles dispersed in a suitable carrier material, preferably an aqueous carrier material. Suitable carriers are known to those skilled in the art. The compositions will usually be prepared in unit dosage form. Preferably, a unit dose will comprise a maximum of 100 mg/kg of the targeting moiety.

The present invention is intended for treatment of human patients and for veterinary applications. However, *in vitro* and *ex vivo* applications are also envisaged.

A particular advantage of the invention for the treatment of cancer is the potential ability to treat all malignant cells in a patient's body, not just those in the main tumour. This is a benefit of the antibody targeting technology, which targets cells having a particular characteristic in any tissue that is reached by the

"targeted" methods that restrict the therapy to a particular anatomical location; for example, the invention described here is less likely to miss metastases.

To take advantage of this, it is preferred that the patient's entire body is subjected to the therapeutic magnetic field. Therefore magnet hardware that is large enough to treat the whole body is preferred, although smaller scale magnets are possible for anatomically localised treatment, including mobile or even hand-held units for low field strength operation. The examples of suitable magnet hardware given here are for whole body units but it is intended that this application covers the option of smaller scale hardware dedicated to particular parts of the anatomy, the basic design principles of which will be apparent to those skilled in the art.

A whole body magnet does not have to treat the entire body simultaneously; it is acceptable to treat a portion at a time. This approach significantly reduces the cost and complexity of the magnet hardware because the working region, over which the magnetic field has the required parameters, need only be large enough to encompass the largest anatomical structure, typically the abdomen. The preferred embodiment therefore creates an approximately spheroid working region in a gap in the magnetic circuit. The patient is passed through the gap, thus exposing the entire body to treatment.

In order to damage the cells, the magnetic nanoparticles must move, and in order to move they must experience a changing force, and hence a changing magnetic field. A range of magnet design options are presented here, covering the range of field strengths required to generate cell damaging forces for a 100nm particle, as calculated above. In each case, the practical range of possible field slew rates is estimated. It will be apparent that these figures will change if the assumptions about particle size or cell damage force threshold change, but the principles of the invention remain valid.

It is desirable to change the direction of the applied field, so that all particles have a good chance of experiencing maximum torque, and to cause the particles to rotate to follow the field direction, thus maximising chances for cell damage. It is also desirable, but not required, to modulate the field amplitude over time, either continuously or in a pulsed fashion. The change in field

direction can be accomplished either by moving (eg: rotating) the patient within a static magnetic field or moving (eg: rotating) the field around the patient. The latter can be achieved either by physically rotating the magnet hardware (Figure 4) or by modulating currents in static electromagnet coils, preferably mounted on a soft iron yoke (Figure 5). In either case, the magnetic field direction should be directed perpendicular to the rotation axis, ie: across the working gap. Various hardware options are feasible to generate such a field, each suited to a different mode of operation and field strength.

Figure 4A is a longitudinal cross-section and Figure 4B a transverse cross-section of a ring-shaped magnet assembly made from prismatic blocks of rare-earth permanent magnet material 15 having fixed magnetization direction shown by arrows 17 defining a Halbach cylinder assembly 10, as known from prior art. Such a structure generates a fairly uniform magnetic field, directed as indicated by an arrow 13, across the bore 11 of a support structure 16 in which a patient 12 is inserted. The magnetic field direction 13 which can be rotated with respect to the patient by rotating the entire magnet assembly 10 around its axis 14. Field strengths of up to 0.2T are envisaged with a slew rate of up to or about 3T/sec, equivalent to about 450rpm, although faster rotation would be possible with suitable mechanical design.

Figures 5A and 5B are similar to Figures 4A and 4B but illustrating a second example in which a set of coils 20, 21 are located on pole pieces 24 connected by a soft iron yoke 23 within a housing 22 having a bore 25 (22 and 25 may define a cryostat). The electromagnets may be resistive or made from high (or low) temperature superconductor. In the case of resistive coils, water cooling will be needed to remove DC losses. In the case of superconducting coils, cryogenic cooling is needed. Rotation of the field direction 13 is caused by driving current in the coils 20, 21 in quadrature. This is a two phase structure but three or more phases could be implemented by using more electromagnets. In the case of superconducting coils, the cryostat must be designed with a high cooling power to absorb AC losses. For this reason, high temperature superconductors may be preferred, as the cost of providing cryogenic cooling

power is inversely proportional to temperature. Magnetic field strengths up to about 0.5T are possible with a slew rate in the range of 1-5T/sec.

Figure 6 illustrates a C-shaped magnet 30 (in transverse cross-section in Figure 6A and longitudinal cross-section in Figure 6B which is similar to the "open" or C-type whole body magnet conventionally used for magnetic resonance imaging (MRI), with coils 31 formed from low temperature superconducting wire mounted on poles 35 connected by a support structure 34, which may optionally be a soft iron yoke to guide flux, which generate a magnetic field having a direction indicated by an arrow 32. The patient 12 is mounted on a support 37 and rotated about their long axis 33. The coils will be located within a cryostat 36 in a conventional manner. In this example, magnetic fields up to about 1T are envisaged with a slew rate of about 1T per second corresponding to rotation of about 150rpm.

Figure 7 is an alternative arrangement of Figure 6, with a second flux return arm, forming a "window-frame" magnet. In all other respects it is similar to the C-magnet.

A further alternative magnet arrangement is based on the example shown in Figures 6 and 7. The magnetic field direction 32 in this embodiment is fixed and the patient is not rotated but the field amplitude is pulsed by varying the current sent to the coils, which may be wound from copper wire or high temperature superconducting wire, as required. ~~Between pulses the magnet~~

hardware or patient can be rotated to a new position to offer the maximum chance of applying a torque impulse to all particles, regardless of orientation.

However, in practice the orientation of the particles will be randomized by Brownian motion, so this step may not be required. The Brownian rotational diffusion time constant is given by

$$\tau_B = 3V\eta / k_B T$$

where η is viscosity. For a 100nm particle this time constant ranges from milliseconds for water ($\eta = 0.89$ centipoise) to seconds for the more viscous

fluids which are likely to be more representative of the intracellular environment ($\eta \sim$ tens of poise). If the time constant for Brownian randomization of particles is short enough it may be acceptable to simply wait for a few seconds before repeating the magnetic field pulse.

In general, some embodiments will share many common features with a magnet for magnetic resonance imaging. However it is important to note that the uniformity of field in the working region required for an MRI magnet is not a requirement for a therapy magnet for use in the current invention. A variation of flux density of 20-30% within the working region is quite acceptable (provided the weakest field is stronger than the threshold for cell damage). In consequence, some magnet embodiments for the present invention may have reduced cost compared to MRI magnets.

As mentioned above, MRI type magnets can be used and in this case, it is feasible that an MR image could be obtained at various stages during the process, and also before and after the process, of the structure in the working volume.

Even if the therapy magnet is not capable of MRI, it may be desirable to use a conventional MRI system to image the patient after administration of the nanoparticles and before magnetic therapy, to ensure correct location of the nanoparticles, which will appear in a suitably constructed MR imaging sequence due to their strong magnetic properties. Such a pre-screening process will also be useful for identifying large ferromagnetic foreign bodies in the patient's body, such as metallic swarf, that would represent a hazard during magnetic therapy.

Although the present invention has been described with emphasis on the disruption of biological material in a therapeutic context, other (non-therapeutic) applications of the disruption method are envisaged. For example, the build up of non-organic materials may be disrupted. In addition, cosmetic applications of the method are also envisaged.

CLAIMS

1. A method for disrupting a material, comprising the steps of:
 - (i) localising one or more magnetic particles at or within the material;
and
 - (ii) applying a magnetic field to the or each magnetic particle, to induce particle movement and thereby disrupt the material, wherein the or each magnetic particle has intrinsic magnetization, said magnetization being stabilised by inherent magneto-crystalline anisotropy and/or by shape anisotropy.
2. A method according to claim 1, wherein the material is a biological material.
3. A method according to claim 1 or claim 2, wherein the material is a cellular or tissue structure.
4. A method according to any preceding claim, wherein the material is a mammalian cell.
5. A method according to any preceding claim, wherein the material is a tumour.
6. A method according to any preceding claim, carried out *in vitro*.
7. A method according to any preceding claim, wherein the or each particle comprises a targeting moiety.
8. A method according to claim 7, wherein the targeting moiety is an antibody.
9. A method according to claim 8, wherein the antibody is a cell-internalising antibody.
10. A method according to any preceding claim, wherein the particle(s) comprise a magnetic material with a magneto-crystalline anisotropy of at least $1 \times 10^5 \text{ J/m}^3$.
11. A method according to claim 10, wherein the magnetic material is a rare-earth metal alloy or a crystalline hexaferrite.
12. A method according to any preceding claim, wherein the particle(s) comprise a coating of a bio-compatible material.

13. A method according to any preceding claim, wherein the magnetic material of the particle(s) is of a maximum dimension of from 50 nm to 500 nm.
14. A method according to any preceding claim, wherein the particle(s) have a total maximum dimension not exceeding 200 nm.
15. A method according to any preceding claim, wherein the particle(s) are substantially cuboid, oblate spheroid or prolate spheroid in shape.
16. A method according to any preceding claim, wherein the applied magnetic field has a flux density of from 0.01 to 2 Tesla.
17. A method according to any preceding claim, wherein the applied magnetic field direction or amplitude with respect to the material is varied over time.
18. A method according to claim 17, wherein the magnetic field variation causes rotation of the particle(s).
19. A method according to claim 17 or claim 18, wherein the magnetic field variation is continuous.
20. A method according to claim 17 or claim 18, wherein the variation is discontinuous, the magnetic field being repeatedly applied after re-orienting the material.
21. A method according to claim 17 or 18, wherein the variation is discontinuous, the magnetic field being repeatedly applied after a predetermined wait period to allow the magnetic axis of the particle(s) to take up a random direction as a result of Brownian motion.
22. A method according to any of claims 17 to 21, wherein the variation is achieved by suitably controlling an external magnetic field generator.
23. A method according to claim 22, when dependent on any of claims 17 to 19, wherein the field direction is varied at a frequency up to 100 Hz.
24. A method according to any of claims 17 to 23, wherein the variation is achieved by moving the material.
25. A method according to claim 23, when dependent on any of claims 17 to 19, wherein the material is moved at a frequency up to 10 Hz.
26. A method according to any of the preceding claims, further comprising obtaining a magnetic resonance image of the particle(s) prior to causing movement of the particle(s).

27. Use of one or more magnetic particles in the manufacture of a medicament for administration to a patient to treat a disorder associated with a cellular or tissue structure, or the accumulation of an undesirable biological material, wherein the or each particle is intended to localise at or within the structure or material, and wherein the treatment is intended to be carried out by applying a magnetic field, to induce the or each particle to move, to thereby disrupt the structure or material, wherein the or each magnetic particle has intrinsic magnetization, said magnetization being stabilised by inherent magneto-crystalline anisotropy and/or by shape anisotropy.
28. Use according to claim 27, wherein the structure is a mammalian cell.
29. Use according to claim 27 or claim 28, wherein the structure is a tumour.
30. Use according to any of claims 27 to 29, wherein the or each particle is as defined in any of claims 7 to 15.
31. Apparatus for disrupting a material, the apparatus comprising a magnetic field generator for generating a magnetic field in a working volume; one or more magnetic particles localized at or in the material in the working volume, wherein the or each magnetic particle has intrinsic magnetization, said magnetization being stabilised by inherent magneto-crystalline anisotropy and/or by shape anisotropy; and a control system for causing a change in the magnetic field in the working volume with respect to the material.
-
32. Apparatus according to claim 31, wherein the control system causes a relative movement between the magnetic field direction and the material.
33. Apparatus according to claim 32, wherein the control system causes a relative rotation between the magnetic field direction and the working volume.
34. Apparatus according to any of claims 31 to 33, wherein the control system is adapted to cause the magnetic field vector in the working volume to change with respect to the material in amplitude or direction or both.
35. Apparatus according to claim 34, wherein the control system is adapted to cause the magnetic field generator to change relative to the material.
36. Apparatus according to claim 31, wherein the control system is adapted to cause the magnetic field generator to pulse the amplitude of the magnetic field in the working volume.

36. Apparatus according to claim 31, wherein the control system is adapted to cause the magnetic field generator to pulse the amplitude of the magnetic field in the working volume.
37. Apparatus according to any of claims 31 to 36, wherein the working volume is located externally of the magnetic field generator.
38. Apparatus according to any of claims 31 to 37, wherein the magnetic field generator comprises one or more electromagnets.
39. Apparatus according to claim 38, wherein the or each electromagnet is fabricated from a high temperature superconductor.
40. Apparatus according to any of claims 31 to 39, wherein the magnetic field generated by the magnetic field generator has a field strength in the range 0.01 to 2 Tesla.
41. A magnetic particle as defined in any of claims 7 to 15.




Fig 1a




Fig 1c




Fig 2




Fig 3a: Oblate spheroid with axis ratio 2.5:1




Fig 3b: Prolate spheroid with $a/b = 1.1$




Fig 4B

Fig 4A

Rotating permanent magnet (Halbach cylinder)




Fig 5B






Fig 5A

2-phase rotating field magnet



Static field C-magnet



Static field window-frame magnet

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.